Table 5.
Distribution for scores and selected factors associated with breast cancer progression.
Dataset was retrieved from our previous study [21]
| Scorea | Total | Non-HT | Tissue visfatin > 50% | LN metastasis | Stage III, IV | Age > 50 years | Tumor size ≥ 2 cm | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (n = 39) | (n = 50) | (n = 40) | (n = 22) | (n = 49) | (n = 57) | ||||||||
| nb | nc | % | nc | % | nc | % | nc | % | nc | % | nc | % | |
| ≤ 2 | 56 | – | 1 | 1.8 | 2 | 3.6 | – | 1 | 1.8 | – | |||
| 3 | 21 | 2 | 9.5 | 2 | 9.5 | 2 | 9.52 | – | 2 | 9.52 | 2 | 9.52 | |
| 4 | 14 | 5 | 35.7 | 5 | 35.7 | 3 | 21.4 | 4 | 28.6 | 5 | 35.7 | 6 | 42.9 |
| ≥ 5 | 14 | 8 | 57.1 | 9 | 64.3 | 8 | 57.1 | 7 | 50.0 | 8 | 57.1 | 9 | 64.3 |
aCumulative score (Table 4) representing the number of risk properties of the selected clinicopathologic factors (HT, tissue visfatin, LN metastasis, stage, age, and tumor size) in patients
bn is the number of all breast cancer patients with disease-free or progressed conditions
cn is the number of breast cancer progressed patients